Two Pediatric Bone Disorders in the Era of Disease Specific Therapies – When to Refer Patients and How to Treat XLH and HPP

CME: 1.0

Target Audience

This activity is designed to meet the educational needs of pediatricians in endocrinology, primary care, rheumatology, orthopedics, neurology, radiology, nephrology, neonatology, and other speciaties. Healthcare providers including geneticists and genetic counselors are included.

Program Overview

X-linked hypophosphatemia (XLH) and hypophosphotasia (HPP) are genetic metabolic bone diseases with recent treatment advances. This program will discuss when to refer and how to treat children with XLH or HPP in the era of disease specific therapies.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review pathophysiology, presentation, and diagnosis of hypophosphatasia (HPP) and X-linked hypophosphatemia (XLH) in children.
  • Evaluate the mechanisms, efficacy, and safety of agents approved for the treatment of HPP and XLH
  • Develop personalized strategies for the long-term management of children with HPP and XLH.

Post a comment to this article